Science Explorer Back to mapMap
Discussion
Institution · Alligator Bioscience (Sweden)

Most cited papers from Alligator Bioscience (Sweden)

Alligator Bioscience (Sweden)

What are the most cited papers from Alligator Bioscience (Sweden)?

The most cited paper from Alligator Bioscience (Sweden) is "The Evolution of the Protein Corona around Nanoparticles: A Test Study" (Martin Lundqvist, Johannes Stigler, Tommy Cedervall et al., 2011), with 799 citations. Next come "Bispecific antibodies in cancer immunotherapy" (212) and "Immunomodulation of enzyme function in plants by single-domain antibody fragments" (187).

Showing 50 of 73 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The Evolution of the Protein Corona around Nanoparticles: A Test Study Martin Lundqvist, Johannes Stigler, Tommy Cedervall et al. · ACS Nano 23 Aug 2011 799
2 Bispecific antibodies in cancer immunotherapy Eva Dahlén, Niina Veitonmäki, Per Norlén · Therapeutic Advances in Vaccines and Immunotherapy Open access Feb 2018 212
3 Immunomodulation of enzyme function in plants by single-domain antibody fragments Stephen A. Jobling, Carl D. Jarman, Min‐Min Teh et al. · Nature Biotechnology 16 Dec 2002 187
4 First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies Sandra Irenaeus, Dorte Lisbet Nielsen, Peter Ellmark et al. · International Journal of Cancer 21 Jan 2019 146
5 The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand et al. · Journal for ImmunoTherapy of Cancer Open access 11 Apr 2019 115
6 The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity Sara M. Mangsbo, Sissela Broos, Erika A.K. Fletcher et al. · Clinical Cancer Research 14 Oct 2014 104
7 Enhancement of seed phytosterol levels by expression of an N‐terminal truncated Hevea brasiliensis (rubber tree) 3‐hydroxy‐3‐methylglutaryl‐CoA reductase Mark Harker, Niklas Holmberg, John C. Clayton et al. · Plant Biotechnology Journal Open access Mar 2003 101
8 Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer Linda C. Sandin, Anna Orlova, Erika Gustafsson et al. · Cancer Immunology Research Open access 21 Oct 2013 100
9 CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation Itziar Otano et al. · Nature Communications Open access 15 Dec 2021 93
10 IgG and fibrinogen driven nanoparticle aggregation Risto Cukalevski, Sílvia A. Ferreira, Christopher J.R. Dunning et al. · Nano Research Open access 20 Jun 2015 90
11 Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo Linda C. Sandin, Fredrik Eriksson, Peter Ellmark et al. · OncoImmunology Open access 2014 86
12 Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer Luuk van Hooren, Linda C. Sandin, Igor Moskalev et al. · European Journal of Immunology Open access 22 Nov 2016 79
13 Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study Jean–Luc Van Laethem, Ivan Borbath, Hans Prenen et al. · The Lancet Oncology Open access Jun 2024 59
14 NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer Aura Kaunisto, Whitney S. Henry, Laleh Montaser‐Kouhsari et al. · Molecular Oncology Open access 19 Feb 2015 48
15 Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation Peter Ellmark, Sara M. Mangsbo, Christina Furebring et al. · Cancer Immunology Immunotherapy Open access 6 Oct 2016 45
16 Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy Maria Georganaki, Mohanraj Ramachandran, Sander Tuit et al. · OncoImmunology Open access 2020 44
17 Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model Jesper van der Pals, Sasha M. Koul, Patrik Andersson et al. · BMC Cardiovascular Disorders Open access 27 Sep 2010 41
18 Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down‐regulating fibrinolysis Wolfgang Knecht, Johan L. Willemse, Hanna Stenhamre et al. · FEBS Journal 25 Jan 2006 41
19 Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy Karin Enell Smith, Adnan Deronic, Karin Hägerbrand et al. · Expert Opinion on Biological Therapy Open access 27 May 2021 39
20 Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression Jonathan P. O. Hebb, Adriane R. Mosley, Felipe Vences‐Catalán et al. · Cancer Immunology Immunotherapy Open access 13 Sep 2017 36
21 Characterization of the substitution pattern of cellulose derivatives using carbohydrate-binding modules Laura von Schantz, Herje Schagerlöf, Eva Nordberg Karlsson et al. · BMC Biotechnology Open access Dec 2014 31
22 Unity in organisation and regulation of catabolic operons in Lactobacillus plantarum, Lactococcus lactis and Listeria monocytogenes Jan Andersson, Douwe Molenaar, Peter Rådström et al. · Systematic and Applied Microbiology Open access Apr 2005 31
23 Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies Karin Hägerbrand et al. · Journal for ImmunoTherapy of Cancer Open access Nov 2022 29
24 Discovery of Selective Small-Molecule CD80 Inhibitors Kristina Uvebrant, Dorthe da Graça Thrige, Anna Rosén et al. · SLAS DISCOVERY Open access 13 Apr 2007 29
25 Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles Sissela Broos, Linda C. Sandin, Jenny Apel et al. · Biomaterials 10 Jun 2012 29
26 Next-generation CD40 agonists for cancer immunotherapy Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson et al. · Expert Opinion on Biological Therapy Open access 3 May 2024 28
27 Novel Insights into the Distribution and Functional Aspects of the Calcium Binding Protein Secretagogin from Studies on Rat Brain and Primary Neuronal Cell Culture Magdalena A. Maj, Ivan Milenković, Jan Bauer et al. · Frontiers in Molecular Neuroscience Open access 2012 28
28 The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo Adnan Deronic, Anneli Nilsson, Mia Thagesson et al. · Cancer Immunology Immunotherapy Open access 5 May 2021 22
29 Identification of conformational epitopes for human IgG on Chemotaxis inhibitory protein of Staphylococcus aureus Erika Gustafsson, Pieter‐Jan Haas, Björn Walse et al. · BMC Immunology Open access 2009 20
30 Defining lncRNAs Correlated with CHO Cell Growth and IgG Productivity by RNA-Seq Davide Vito, Jens Christian Eriksen, Christian Skjødt et al. · iScience Open access 18 Dec 2019 18
31 An oat bran meal influences blood insulin levels and related gene sets in peripheral blood mononuclear cells of healthy subjects Matilda Ulmius, Anna Johansson‐Persson, Morten Krogh et al. · Genes & Nutrition Open access 18 May 2011 18
32 Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases Emila Kurbasic, Martin Sjöström, Morten Krogh et al. · Clinical Proteomics Open access 11 May 2015 18
33 Kick-starting the cancer-immunity cycle by targeting CD40 Peter Ellmark, Sara M. Mangsbo, Christina Furebring et al. · OncoImmunology Open access 16 Mar 2015 18
34 Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T‐cells and regulatory T‐cells in TP53 ‐mutated acute myeloid leukemia Milad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn et al. · Cancer Medicine Open access 16 Mar 2022 16
35 Rapid personalized AMR diagnostics using two-dimensional antibiotic resistance profiling strategy employing a thermometric NDM-1 biosensor Qinglai Meng, Shichao Liu, Jinhua Meng et al. · Biosensors and Bioelectronics Open access 21 Jul 2021 14
36 Purification of truncated and mutated Chemotaxis Inhibitory Protein of Staphylococcus aureus—an anti-inflammatory protein Erika Gustafsson, Cecilia Forsberg, Karin Haraldsson et al. · Protein Expression and Purification 6 Oct 2008 14
37 Directed evolution of chemotaxis inhibitory protein of Staphylococcus aureus generates biologically functional variants with reduced interaction with human antibodies Erika Gustafsson, Anna Rosén, Karin Barchan et al. · Protein Engineering Design and Selection 3 Dec 2009 13
38 Proteomic analysis of breast tumors confirms the mRNA intrinsic molecular subtypes using different classifiers: a large-scale analysis of fresh frozen tissue samples Sofia Waldemarson, Emila Kurbasic, Morten Krogh et al. · Breast Cancer Research Open access 29 Jun 2016 12
39 The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies Michelle Hase Nelson et al. · Molecular Cancer Therapeutics Open access 7 Nov 2022 11
40 REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer Songul Kucukcelebi et al. · Nature Communications Open access 28 Nov 2025 10
41 ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1 Karin Enell Smith, Sara Fritzell, Anneli Nilsson et al. · Cancer Immunology Immunotherapy Open access 5 Oct 2023 10
42 Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics Johan Fransson, Sara Ek, Peter Ellmark et al. · Cancer Letters 10 Feb 2004 10
43 RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties Barnabas Nyesiga, Mattias Levin, Anna Säll et al. · mAbs Open access 25 Mar 2024 8
44 Age related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer’s pathology Magdalena A. Maj · World Journal of Diabetes Open access 2011 8
45 Pre‐assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti‐immunoglobulin M‐induced apoptosis Peter Ellmark, CHRISTINA, FUREBRING et al. · Immunology Open access Apr 2003 8
46 Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody Hampus Andersson, Aastha Sobti, David Gomez Jimenez et al. · Cells Open access 27 Sep 2023 7
47 A novel direct screening method for alkyl glucoside production by glucosidases expressed in E. coli in 96-well plates Martin Gräber, Mats R. Andersson, Fabian Rundbäck et al. · Journal of Biotechnology 14 Nov 2009 7
48 Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay Qinglai Meng, Yao Wang, Yali Long et al. · Antibiotics Open access 14 Sep 2021 6
49 Development of Interleukin-1 Receptor Antagonist Mutants with Enhanced Antagonistic ActivityIn Vitroand Improved Therapeutic Efficacy in Collagen-Induced Arthritis Eva Dahlén, Karin Barchan, Daniel Herrlander et al. · Journal of Immunotoxicology Open access 2008 6
50 Will reducing agricultural runoff drive recovery of coral biodiversity and macroalgae cover on the Great Barrier Reef? Peter Ridd, Alan R. Orpin, Thomas C. Stieglitz et al. · Ecological Applications Open access Dec 2011 6

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.